Business Development Deal Architecture
  • Search OnBioBD:

  • OnBioBD OldSkool NEWS:

    - OnBioVC 4Q11 Trend Analysis, now available
    - OnBioVC 1Q12 White Paper, now available
    - OnBioVC 1Q12 Trend Analysis, coming soon

  • FDA Registered Contract Manufacturer

Tensha Therapeutics (Cambridge, MA) a preclinical-stage pharmaceutical company focused on midline carcinoma, acute myeloid leukemias and multiple myeloma, closed a $15M Series A financing. Participants include HealthCare Ventures.

Constellation Pharmaceuticals (Cambridge, MA) a development-stage biopharma focused on small molecule therapeutics against chromatin-based targets to treat cancer and inflammatory disorders, closed a $15M Series B financing bringing the total round to $37M. Participants include S.R. One, Altitude Life Science Ventures, Third Rock Ventures, The Column Group and Venrock. The 2Q11 OnBioVC Trend Analysis will […]

Constellation Pharmaceuticals (Cambridge, MA) a development-stage biopharma focused on epigenetic therapeutic development in the field of oncology, closed a $4.8M Series B financing bringing the total round to $22M. Participants include S.R. One, Altitude Life Science Ventures, Third Rock Ventures, The Column Group and Venrock.

Epizyme (Cambridge, MA) a development-stage biopharma company focused on histone methyltransferases inhibitors in oncology indications, closed a $8M Series B financings, bringing the total round to $40M. Participants include New Enterprise Associates, Bay City Capital, Amgen Ventures, Astellas Venture Partners, MPM Capital and Kleiner Perkins Caufield and Byers. Note: 2009 Year-in-Review Trend Analysis Coming 15 […]

Epizyme (Cambridge, MA) a development-stage biopharma company focused on histone methyltransferases inhibitors in oncology indications. Participants include Bay City Capital, Amgen Ventures, Astellas Venture Management, MPM Capital and Kleiner Perkins Caufield and Byers. Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb.

Constellation Pharmaceuticals (Cambridge, MA) a development-stage biopharma focused on epigenetic therapeutic development in the field of oncology, closed a $17.2M Series B financing. Participants include Altitude Life Science Ventures, Third Rock Ventures, The Column Group and Venrock.

Constellation Pharmaceuticals (Cambridge, MA) development-stage biopharmaceutical company focused on discovering and developing novel drugs targeting selective regulators of epgenetic function, closed a $32M Series A financing. Participants include Third Rock Ventures, Column Group, and Venrock

  

to top of page...